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Abstract
Cells utilize multiple autophagy pathways to sequester macromolecules, senescent organelles, and 
pathogens. Several conserved isoforms of the lysosome-associated membrane protein (LAMP)-2 
regulate these pathways influencing immune recognition and responses. LAMP-2A is required for 
chaperone-mediated autophagy (CMA) which promotes Ag capture and MHC class II (MHCII) 
presentation in B cells and signaling in T cells. LAMP-2B regulates lysosome maturation to 
impact macroautophagy (MA) and phagocytosis. Yet, far less is known about LAMP-2C function. 
While LAMP2A and LAMP2B mRNA were broadly detected in human tissues, LAMP2C 
expression was more limited. Transcripts for the three LAMP2 isoforms increased with B cell 
activation, although specific gene induction varied depending on TLR versus BCR engagement. 
To examine LAMP-2C function in human B cells and specifically its role in Ag presentation, 
ectopic gene expression was used. Increased LAMP-2C expression in B cells did not alter MHCII 
expression or invariant chain processing, but did perturb cytoplasmic Ag presentation via CMA. 
MHCII presentation of epitopes from exogenous and membrane Ags was not affected by 
LAMP-2C expression in B cells. Similarly, changes in B cell LAMP-2C expression did not impact 
MA. The gene expression of other LAMP2 isoforms as well as the proteasome and lysosomal 
proteases activities were unperturbed by LAMP-2C ectopic expression. LAMP-2C levels 
modulated the steady-state expression of several cytoplasmic proteins which are targeted for 
degradation by CMA and diminished peptide translocation via this pathway. Thus, LAMP-2C 
serves as a natural inhibitor of CMA which can selectively skew MHCII presentation of 
cytoplasmic Ags.
Introduction
MHC class II (MHCII) molecules, displayed on the surface of APCs, present self and 
foreign antigenic peptides to CD4+ T lymphocytes. The presentation of peptides derived 
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from exogenous proteins initiates immunological responses, whereas the presentation of 
self-derived epitopes is critical for the development of self-tolerance. MHCII αβ 
heterodimers are synthesized and co-assembled with invariant chain (Ii) in the endoplasmic 
reticulum (1). Aspartic and cysteine proteases degrade Ii once this complex reaches the late 
endosomal compartment known as MIIC, generating CLIP which remains bound to the 
peptide binding groove of MHCII (2, 3). In the presence of antigenic epitopes, HLA-DM 
catalyzes the removal of CLIP from the MHCII peptide binding groove and facilitates 
antigenic peptide binding (4, 5). MHCII-peptide complexes are then transported to the cell 
surface and presented to CD4+ T cells. MHCII classically presents epitopes derived from 
exogenous Ags that are internalized through endocytosis for processing in endosomes and 
lysosomes (6). Cell surface and endosomal membrane Ags derived from infectious agents or 
self-proteins are similarly proteolyzed yielding abundant peptide ligands for MHCII (7, 8). 
Constitutive and stress-modulated degradation pathways such as macroautophagy (MA) and 
chaperone-mediated autophagy (CMA) sequester cytoplasmic and nuclear proteins into 
endosomes and lysosomes, giving rise to roughly 10–30% of the antigenic peptides 
presented by MHCII.
MA is constitutively active at low levels in most immune cells and can be induced by stress 
or infection, driving the formation of double membrane vesicles known as autophagosomes 
which sequester cytosolic contents including pathogens and organelles. Fusion of 
autophagosomes with lysosomal compartments results in vesicular content degradation 
giving rise to fragmented macromolecules. This autophagy pathway is important for 
pathogen elimination, regulation of pattern recognition receptors and the inflammasome, Ag 
presentation, and T and B cell homeostasis (9–11). CMA provides another pathway for 
surveillance of the cytoplasm which facilitates MHCII presentation of epitopes derived from 
specific cytoplasmic Ags. During CMA, select cytoplasmic proteins are targeted and 
recognized by association with HSC70 and HSP90 (12). This chaperone complex interacts 
with lysosome-associated membrane protein (LAMP)-2A, driving the translocation of 
targeted proteins and peptides into the lysosome for processing and in some cases, binding 
to MHCII. CMA is also modulated during periods of stress such as nutrient deprivation and 
oxidative stress as well as with cell transformation and aging (13–15).
LAMP-2A belongs to a family of highly homologous type I transmembrane proteins, each 
with a conserved glycosylated domain extending into the acidic lysosomal lumen. In 
humans, LAMP-2 (CD107b) protein is derived from a single gene with nine exons. 
Alternative splicing of exon nine generates three isoforms known as LAMP-2A, LAMP-2B, 
and LAMP-2C, which differ primarily in the sequence of their transmembrane and cytosolic 
tail (Fig. 1A). In patients with the inherited disorder Danon disease, deficiencies in LAMP-2 
result in impaired MHCII presentation of exogenous but not membrane Ags, as well as 
disruptions in lysosome biogenesis and phagocytosis (16, 17). LAMP-2A is known to 
function biologically in lysosomes as the translocator for CMA. During CD4+ T cell 
activation, LAMP-2A protein expression increases and promotes the ubiquitin ligase
Itch and the calcineurin inhibitor RCAN1 degradation via CMA to extend cell signaling 
(18). In B cells, MHCII-restricted presentation of several cytoplasmic autoantigens is 
dependent on LAMP-2A expression (19). LAMP-2B by contrast, modulates lysosome 
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fusion and possibly MA, although its role in Ag presentation is less clear as ectopic 
expression of this isoform in human B lymphocytes did not alter MHCII presentation (17, 
19). Recent publications have implicated LAMP-2C in the uptake and degradation of RNA 
and DNA molecules (20, 21). However, the importance and role of LAMP-2C in immune 
recognition remains to be elucidated. In the current study, distinct gene expression patterns 
for LAMP2 isoforms were revealed with human B cell activation via BCR crosslinking and 
TLR ligand exposure. Given increased LAMP2C expression in response to B cell activation, 
the role of this isoform in modulating MHCII Ag presentation and autophagy pathways was 
determined. LAMP-2C functioned as a novel endogenous negative regulator of CMA which 
disrupted molecular translocation into lysosomes but did not alter MA. Increased cellular 
expression of LAMP-2C also skewed MHCII Ag presentation by disrupting cytoplasmic 
epitope presentation to CD4+ T cells.
Materials and Methods
Cell Lines
Human B lymphoblastoid cell lines (B-LCL) PriessGAD and FrevSMA cells have been 
described (19) and were maintained in IMDM with 10% heat-inactivated FCS, 50 U/ml 
penicillin, and 50 μg/ml streptomycin. T cell hybridomas recognizing epitopes presented by 
HLA-DR4, 33.1 (specific for GAD273-285), 2.18 (specific for Ig κI188-203), 1.21 (specific for 
Ig κII145-159), 17.9 (specific for HSA64-76), 49.23.2 (specific for an epitope of tetanus toxin), 
1736-DR4-3B2 (specific for an epitope of MP1 provided by Dr. D. Canaday, Case Western 
University), and 50.84.17 (specific for HA307-319) were cultured in RPMI-1640 with 10% 
FBS, 0.1% 2-ME, 50 U/ml penicillin, and 50 μg/ml streptomycin.
Plasmids and Cell Transfection
LAMP2C cDNA was inserted into the vector pcDNA3.1/Zeo (−) via EcoRV and BamHI 
restriction sites or into the vector pCMV Tag-1 via SacI and SalI restriction sites. 
PriessGAD B-LCL were transfected with linearized plasmid (10–20 μg/ml) by 
electroporation (250 V, 950 μF) and incubated on ice 10 min. Transfection of FrevSMA B-
LCL was achieved using Xfect Transfection Reagent (Clontech). PriessGAD zeo and 
PriessGAD 2c were transduced to express the cytoplasmic influenza A matrix protein 1 
(MP1) fused to the autophagy protein LC3 using a lentiviral vector provided by Dr. C. Münz 
(University of Zurich) (22). Drug-resistant cell lines were selected and screened for target 
gene expression.
RT-PCR
For detecting LAMP2 isoform expression, a cDNA panel of human tissue was purchased 
from Clontech. The 5’ primer for all three LAMP2 isoforms was 5’-
GAAGGAAGTGAACATCAGCATG-3’, the 3’ primer for LAMP2A was 5’-
CTCGAGCTAAAATTGCTCATATCCAGC-3’, for LAMP2B was 5’-
CAAGCCTGAAAGACCAGCACC-3’, and for LAMP2C was 5’-
CTCGAGTTACACAGACTGATAACCAGTAC-3’. The 5’ primer for GAPDH was 5’-
ATGGCACCGTCAAGGCTGAG-3’ and the 3’ primer was 5’-
TGCAGGAGGCATTGCTGATG-3’. Platinum PCR supermix (Invitrogen) was used for 
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amplification. LAMP2 cDNAs were amplified for 35 cycles. To detect SMA expression, 
cellular RNA was extracted using RNeasy Mini Kit (Qiagen) and cDNA was generated 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). The 5’ 
primer for SMA was 5’-GACTCTGGTCTTCATATCCATACTGCT-3’ and the 3’ primer 
was 5’-GCAGTAATAAACGGCTACATCTTCA-3’. SMA cDNA was amplified using 2X 
Reddy Mix PCR Master Mix (Thermo Scientific) for 35 cycles. GAPDH cDNA was 
amplified for 30 cycles. PCR products were resolved on an agarose gel.
Real-Time Quantitative PCR (qPCR)
RNA was extracted from human and mouse tissues or human B cells and used to prepare 
cDNA. qPCR was performed using the 7500 Fast RT-PCR System (Applied Biosystems) 
and TaqMan primers for LAMP2A, LAMP2B, and LAMP2C (Supplemental Fig. 1A) or 
commercially available TaqMan primers for CD86, GAPDH, or 18S rRNA. qPCR was 
performed using TaqMan primers designed for detection of murine Lamp2a, Lamp2b, and 
Lamp2c (Supplemental Fig. 1A) or commercially available TaqMan primers for murine Actb 
(Applied Biosystems). Gene expression in B cells was normalized to 18S rRNA or GAPDH 
mRNA levels and presented as an arbitrary fold change (RQ) compared to control samples. 
Gene expression in tissue samples was presented as mRNA expression relative to GAPDH 
or Actb mRNA levels.
Semi-nested qPCR
For detection of LAMP2C in human peripheral blood B cells, spleen, or muscle, two rounds 
of PCR amplification were used. LAMP2C cDNA was amplified 10 cycles using 2 μl of total 
cDNA, Platinum Taq DNA Polymerase High Fidelity (Invitrogen), and 0.2 μM of primers 
for LAMP2C. qPCR was performed using TaqMan primers for LAMP2C with 0.5 μl of the 
first PCR for semi-nested qPCR.
Antibodies
LAMP-1 (H4A3) and LAMP-2 (H4B4) Abs were from the Developmental Studies 
Hybridoma Bank (University of Iowa). DA6.147 Ab recognizes HLA-DR αchain (P. 
Cresswell, Yale University). L243 Ab recognizes HLA-DR αβ dimers and pin1.1 Ab detects 
Ii. The Ab for GILT was developed in our laboratory. HSC70 and HSP90 Abs were from 
Enzo Life Sciences, GAD65/67 Ab from Sigma-Aldrich, and cathepsin D Ab from 
Calbiochem. LC3 and p-IκBα Abs were obtained from Cell Signaling. Actin and RNAse A 
Abs were from Thermo Scientific. GAPDH Ab was from Millipore. HLA-DQ Ab was from 
Abcam and HLA-DP and HLA-DOβ Abs from Santa Cruz Biotechnology, Inc. were used in 
flow cytometry. FITC tagged CerClip Ab was used to detect CLIP and FITC labeled HLA-
DR Ab to detect HLA-DR αβ dimers by flow cytometry (BD Biosciences).
Flow Cytometry
For detection of surface CLIP, HLA-DR, -DP, or -DQ, APCs were incubated 1 h on ice with 
appropriate Ab. APCs were washed with FACS buffer (PBS, 1% BSA, 0.1% NaN3) and 
fixed with 1% paraformaldehyde (PFA). For detection of intracellular HLA-DO, APCs were 
fixed with PFA, permeabilized with 0.1% saponin, blocked with goat serum, and incubated 
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for 1 h on ice with an Ab to detect HLA-DO followed by FITC labeled rabbit anti-mouse Ab 
(Sigma-Aldrich). Samples were washed with FACS buffer before analysis. Flow cytometry 
was performed on BD LSR II and analyzed using FlowJo software (Tree Star).
Immunoblotting
APCs were lysed on ice for 30 min with 10 mM Tris-HCl pH 6.8, 150 mM NaCl, 1% 
Triton-X 100, protease inhibitor cocktail (Sigma-Aldrich). 50 μg-80 μg protein from lysates 
were resolved on SDS-PAGE and transferred to nitrocellulose (Bio-Rad). Membranes were 
probed with specific primary Ab and incubated with goat anti-mouse-, anti-rabbit-, or anti-
rat-HRP conjugated secondary Ab (Jackson ImmunoResearch Laboratories, Inc.). Blots 
were visualized with ECL reagent (Pierce).
Immunoprecipitation
APCs were lysed 30 min on ice with 50 mM Tris-HCl pH 8, 150 mM NaCl, 1% Igepal 
CA630 (Sigma-Aldrich), protease inhibitor cocktail (Sigma-Aldrich). Lysates were 
incubated with 5 μg/ml of HSC70 Ab or isotype control overnight at 4°C. Protein complexes 
were co-immunoprecipitated using μMACS Protein G Microbeads and μ Columns (Miltenyi 
Biotec). Samples were resolved on SDS-PAGE and analyzed by immunoblotting.
Ag Presentation Assay
To measure endogenous Ag presentation, APCs were co-cultured for 24 h at 37°C with 
epitope specific T cells. For exogenous Ag presentation, APCs were incubated with 
synthetic peptides or purified Ag for 4 or 16 h at 37°C and then co-cultured with epitope 
specific T cells for 24 h at 37°C. For HA Ag presentation, APCs were infected for 16 h with 
live influenza A X-31, A/Aichi/68 (H3N2) (Charles River) and then co-cultured with 
epitope specific T cells for 24 h at 37°C. APCs were cultured with T cells at variable APC:T 
cell ratios. An IL-2 dependent T cell line, HT-2, was used to measure IL-2 produced in 
response to T cell activation. HT-2 proliferation was evaluated by [3H] thymidine 
incorporation and quantified by liquid scintillation counting (Wallac Microbeta).
MA Flux
APCs were incubated for 16 h at 37°C +/− 20 μM chloroquine (CQ) (Sigma-Aldrich). 
Immunoblotting was used to detect cellular LC3II. Protein levels were determined by 
densitometry using ImageJ software (NIH). LC3II was normalized to GAPDH protein 
levels. MA flux was determined by subtracting normalized LC3II levels of untreated cells 
from normalized LC3II levels of CQ treated cells.
Peptide Electroporation
APCs were washed with cold PBS twice and incubated with a GAD273-285, KFERQ-
GAD273-285, or AFERQ-GAD273-285 peptide C-terminal labeled with biotin for 5 min on 
ice. Electroporation (270 V, 125 μF, pulsed twice) was performed using the BIO-RAD gene 
pulser II to deliver the peptide into the cell cytoplasm. Control cells were incubated with 
peptides without electroporation. Cells were extensively washed immediately after 
electroporation and cultured at 37°C for 16 h. APCs were used in an Ag presentation assay 
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or proteins were resolved by SDS-PAGE to detect GAD273-285-biotin/MHCII complexes. 
For PAGE, samples were transferred to nitrocellulose, incubated with streptavidin-HRP and 
ECL reagent (Pierce). Protein levels were determined by densitometry using ImageJ 
software (NIH).
B cell activation
B cells were isolated from healthy adult PBMCs using CD19 MACS beads (Miltenyi 
Biotec) and incubated at 37°C for 24 h with 20 μg/ml of AffiniPure F(ab’)2 Goat Anti-
Human IgG + IgM (H+L) (Jackson ImmunoResearch Laboratories, Inc.), 2 μg/ml of TLR7 
agonist R848 (Enzo Life Sciences), or 50 nM of TLR9 agonist CpG ODN 2006 (Invivogen). 
Cells were harvested, and LAMP2 and CD86 mRNA levels measured by qPCR.
ELISA
Cell culture supernatants from human B cells after 24 h of TLR stimulation were analyzed 
using a standard sandwich ELISA in triplicate to detect IL-6 (Invitrogen).
Protease and Proteasome Assays
For real time analysis of cathepsin B and L activities, the Magic Red™ Cathepsin B and L 
Kits (Immunochemistry Technologies) were used. Fluorescence was detected using flow 
cytometry. Proteasome activity was determined using Proteasome-Glo™ Chymotrypsin-
Like Cell-Based Assay (Promega). Luminescence was detected using a plate reader.
Results
LAMP2 isoform expression in human B lymphocytes
Lamp2c expression is regulated during morphogenesis in mice with some indication of 
tissue-specific distribution (20). Here, studies of the mRNA expression profile for the three 
isoforms in human tissues revealed that LAMP2A and LAMP2B were ubiquitously expressed 
while LAMP2C had a more restricted tissue distribution (Fig. 1B). Quantitative analysis of 
human spleen and muscle substantiated tissue-specific differences for LAMP2C compared 
with LAMP2A or LAMP2B, suggesting distinct regulation and possibly function for 
LAMP2C (Supplemental Fig 1B). Differences in isoform expression were also apparent in 
murine tissues (Supplemental Fig. 1C). LAMP-2A and LAMP-2B proteins are known to 
modulate autophagy pathways impacting B cell function and development (11, 19). To 
address whether differential regulation of LAMP2 isoforms is observed in B cells, peripheral 
blood human B cells were stimulated with TLR7 or TLR9 agonists, R848 or CpG 
respectively. The mRNA encoding each LAMP2 isoform was increased by TLR7 or TLR9 
stimulation with expression strikingly higher in B cells stimulated with CpG (Fig. 1C). Of 
the three isoforms, the relative increase in LAMP2C expression was greatest with B cell 
TLR activation. Changes in CD86 mRNA levels and IL-6 secretion confirmed B cell 
activation with R848 or CpG stimulation (Fig. 1C, 1D). Crosslinking of surface BCR also 
induces B cell activation and proliferation. LAMP2 mRNA levels were evaluated in 
peripheral blood human B lymphocytes after BCR crosslinking, with the relative expression 
of each LAMP2 isoform increasing upon B cell activation (Fig. 1E). Here, higher CD86 
mRNA levels corroborated B cell activation (Fig. 1E). Yet, in contrast to TLR activation, 
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with BCR crosslinking LAMP2C mRNA relative expression increased significantly less than 
LAMP2A or LAMP2B isoforms. These results suggest that expression of LAMP2 isoforms 
may be distinctly regulated during B cell activation.
LAMP-2C expression impacts cytoplasmic Ag presentation via MHCII
The CMA translocator, LAMP-2A, regulates protein and peptide delivery from the 
cytoplasm into lysosomes. Overexpression of LAMP-2A but not LAMP-2B in human B 
cells increased cytoplasmic Ag presentation via MHCII (19). Given B cell activation by 
TLR ligands and BCR crosslinking can alter multiple steps in Ag processing and 
presentation including changes in co-stimulatory molecule expression and HLA-DM 
localization, ectopic expression of LAMP-2C was used to dissect the role of this lysosomal 
protein in Ag presentation. Human B lymphoblasts express low levels of LAMP2C, yet can 
be readily transfected with LAMP2C cDNA to promote higher ectopic expression 
(Supplemental Fig. 1D–F). LAMP2A and LAMP2B mRNA levels were unchanged with 
LAMP2C ectopic expression in B cells (Supplemental Fig. 1D, 1E). To assess the function 
of LAMP-2C in MHCII-restricted presentation, the B cell line PriessGAD expressing 
ectopic LAMP-2C (PG 2c) or transfected with a control vector (PG zeo) were analyzed for 
MHCII presentation of the cytoplasmic Ag glutamate decarboxylase (GAD), which relies 
upon CMA for epitope delivery to MHCII. Interestingly, MHCII presentation of cytoplasmic 
GAD Ag was decreased in cells overexpressing LAMP-2C (Fig. 2A). As a control, 
presentation of exogenous GAD273–285 peptide was tested, and no differences in T cell 
recognition were detected in LAMP-2C expressing cells (Fig. 2B). To further address the 
role of LAMP-2C, another human B- LCL, FrevSMA, was transfected with an empty vector 
(FS pCMV) or a plasmid encoding LAMP2C cDNA (FS 2c). FrevSMA cells express the 
cytoplasmic autoantigen SMA, a mutated form of Ig κ light chain trafficked to the cytosol 
for degradation. Translocation of SMA epitopes from the cytoplasm to MHCII also depends 
upon CMA (19). LAMP2 isoforms mRNA and protein levels were analyzed to confirm 
ectopic expression of LAMP-2C in FS 2c cells (Supplemental Fig. 1E, 1F). Ectopic 
expression of LAMP-2C in these B cells diminished SMA autoantigen presentation by 10 
fold compared with cells with wild-type levels of LAMP-2C (Fig. 2C). As a control, the 
presentation of exogenous κ188-203 peptide was evaluated, and no differences in peptide 
presentation were detected using B cells with ectopic LAMP-2C expression (Fig. 2D). 
Together, these data suggest that LAMP-2C inhibits the MHCII presentation of cytoplasmic 
Ags that rely upon the CMA pathway.
MHCII presentation of exogenous or membrane derived Ags was not altered by LAMP-2C 
expression
To gain a better understanding of the role of LAMP-2C in MHCII Ag presentation, B cells 
expressing LAMP-2C were incubated with exogenous protein Ags, human serum albumin 
(HSA) or tetanus toxoid (TT) which require endocytic uptake and processing to yield 
epitopes for MHCII. Presentation of HSA or TT epitopes derived from these exogenous Ags 
was unperturbed by changes in cellular LAMP-2C expression as assessed by T cell 
activation (Fig. 3A, 3B). Also, presentation of exogenously added HSA64-76 peptide or TT 
peptides was similar for control cells or cells with ectopic LAMP-2C expression (Fig. 3A, 
3B). PriessGAD cells constitutively produce secretory Ig κ light chain, which serves as an 
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endogenous intravesicular source of Ag. For these Ig κ positive B cells, changes in 
LAMP-2C expression did not alter T cell recognition and responses to these membrane 
epitopes (Fig. 4A, 4B). The presentation of a viral membrane glycoprotein, hemagglutinin 
(HA), via MHCII was next examined. During influenza virus replication, newly synthesized 
HA molecules are trafficked through the Golgi compartments to reach the host cell 
membrane for virion formation and budding. Some HA molecules re-enter the endosomal 
network and are processed by acidic proteases, with the resulting epitopes binding MHCII 
molecules followed by the transit of these complexes to the surface for recognition by T 
cells. Ectopic expression of LAMP-2C in B cells did not diminish MHCII presentation of 
HA-derived epitopes as determined by T cell responses to virus-infected cells (Fig. 4C). To 
ensure optimal detection of changes in T cell responses, studies were carried out using a 
range of APC:T cell ratios (Fig. 4). These data suggest that MHCII presentation of Ags 
which enter cells via endocytosis or by the secretory pathway was not altered by changes in 
cellular LAMP-2C expression.
Alterations in cellular LAMP-2C levels failed to perturb MA in B cells
In B cells, MA sequesters cytoplasmic and nuclear Ags to deliver these molecules into 
autophagosomes for processing and subsequent MHCII presentation (23). Cellular stress 
including nutrient deprivation can up-regulate MA while blocking CMA (24). To examine if 
LAMP-2C expression modulates MA and Ag presentation via this pathway, B cells with and 
without ectopic LAMP-2C expression were transduced to express a fusion protein encoding 
the influenza matrix protein MP1 that is targeted to autophagosomes by the LC3 domain 
(22). These cells were co-culture with MP1 specific CD4+ T cells. Ectopic expression of 
LAMP-2C in PG 2c cells had no effect on MP1 Ag presentation (Fig. 5A). Autophagosome 
formation and turnover were monitored to further address whether cellular LAMP-2C levels 
impact MA. MA flux was evaluated by detecting changes in cellular LC3II levels +/− CQ. 
Similar LC3II protein levels detected in these cells indicate that MA was not altered by 
LAMP-2C expression (Fig. 5B). These results suggest that LAMP-2C affects the 
presentation of cytoplasmic Ags processed through CMA without altering MA.
Changes in LAMP-2C expression in B cells failed to alter the expression of key 
components of CMA and the MHCII pathway
LAMP-2 proteins reside primarily in lysosomes, with LAMP-2A regulating CMA and 
LAMP-2B playing a role in lysosome maturation (17, 25). Here we corroborated that 
cellular levels of molecules involved in CMA were not altered by the ectopic expression of 
LAMP-2C in B cells. Levels of the CMA substrates, GAD and SMA, were not disturbed in B 
cells ectopically expressing LAMP-2C (Fig. 6A, Supplemental Fig. 2A). Comparable levels 
of CMA chaperones HSP90 and HSC70 were observed in B cells expressing ectopic 
LAMP-2C or control cells (Fig. 6A). The expression of another lysosome-resident 
glycoprotein, LAMP-1, was unaltered with ectopic LAMP-2C in cells suggesting lysosome 
number and maturation were preserved (Fig. 6A). Immunoblotting analysis revealed that 
MHCII and Ii protein levels did not vary in B cells with ectopic LAMP-2C (Fig. 6B, 
Supplemental Fig. 2B). Furthermore, identical cell surface levels of the Ii peptide CLIP 
which associates with MHCII were detected by flow cytometry in these cells, suggesting 
that HLA-DM peptide editing function was not altered by LAMP-2C expression in B cells 
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(Fig. 6C). Another class II-like molecule, HLA-DO, functions as a modulator of HLA-DM 
(26). Consistent with the lack of change in CLIP expression, HLA-DO levels were 
unchanged with ectopic LAMP-2C expression in B cells (Fig. 6C, Supplemental Fig. 2C). 
Cell surface levels of MHCII molecules HLA-DR, -DQ, and -DP were also not altered in B 
cells overexpressing LAMP-2C (Fig. 6C, Supplemental Fig. 2C). Therefore, LAMP-2C 
expression does not affect cellular levels of well-established co-chaperones involved in 
CMA or key components of the MHCII pathway.
Studies have shown that lysosomal proteinases, such as cathepsin D (CatD), cathepsin B 
(CatB), and cathepsin L (CatL), play a role in MHCII-restricted presentation (27). These 
aspartyl and cysteinyl endoproteinases are required for Ag processing and Ii degradation (2, 
3, 27). Differences in lysosomal proteinase levels can influence the peptide repertoire 
generated in lysosomal compartments, thus impacting the epitopes displayed for MHCII 
presentation. Ectopic expression of LAMP-2C in B cells did not alter cellular CatD subunit 
maturation or expression as detected in immunoblot assays (Fig. 7A). In addition, cells 
incubated with fluorogenic substrates specific for CatB or CatL revealed that the function of 
these cysteinyl endoproteinases was not altered by increased expression of LAMP-2C within 
lysosomal compartments (Fig. 7B). MHCII Ag presentation can also be facilitated by a 
lysosomal thiol reductase, gamma-interferon inducible lysosomal thiol reductase (GILT), 
which is abundantly expressed in professional APCs (8, 28). Immunoblotting analysis 
revealed that LAMP-2C overexpression in B cells did not interfere with GILT maturation or 
expression (Fig. 7A).
Some cytosolic Ags are dependent on the proteasome for MHCII-restricted presentation 
(29). Therefore, we investigated the ability of the proteasome to cleave a luminogenic 
chymotrypsin-like substrate as a means to quantitate the proteasome proteolytic activity in B 
cells expressing ectopic LAMP-2C. This functional assay indicated that the substrate was 
equally cleaved by the proteasome in B cell lines regardless of the level of cellular 
LAMP-2C (Fig. 7C). These results indicate that LAMP-2C, while negatively regulating Ag 
presentation via CMA, does not directly impair the function of Ag processing enzymes 
including cathepsins, GILT, and the proteasome.
Ectopic expression of LAMP-2C reduced the translocation of a cytoplasmic peptide to 
MHCII complexes
The delivery of peptides from the cytoplasm to vesicular MHCII molecules was enhanced in 
B cells with overexpression of the CMA receptor LAMP-2A (19). This led us to question if 
the transport of peptides from the cytoplasm to MHCII complexes was also influenced by 
cellular expression of LAMP-2C. A biotin-labeled GAD273-285 peptide was introduced by 
electroporation into the cytoplasm of B cells expressing variable levels of LAMP-2C 
protein. Electroporation facilitates the delivery of antigenic peptides into the cytoplasm of B 
cells where these are selected by the CMA pathway for translocation into acidic endosomes 
or lysosomes (19). The translocated peptide can then be captured by MHCII molecules 
within these vesicular compartments. Strikingly, ectopic LAMP-2C expression in B cells 
reduced the abundance of newly formed MHCII-GAD peptide complexes, consistent with a 
role for LAMP-2C in blocking CMA (Fig. 8A). As a control, B cells were incubated with 
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peptides without electroporation which blocked cytoplasmic delivery and the formation of 
MHCII-peptide complexes (Fig. 8A). Consistent with this assay which detects epitope 
loading, MHCII presentation of the cytoplasmic GAD peptide was also reduced with ectopic 
LAMP-2C expression in B cells (Supplemental Fig.3A). To determine if the inhibitory 
effects of LAMP-2C on CMA could be overcome, a KFERQ motif which promotes HSC70 
chaperone binding to CMA substrates was added to GAD peptide. Presentation of this 
modified peptide was still reduced in B cells ectopically expressing LAMP-2C 
(Supplemental Fig. 3A). Surprisingly, adding the KFERQ motif to GAD peptide also 
slightly diminished its presentation in B cells transfected with a control vector 
(Supplemental Fig. 3A). Similar results were seen with a control GAD peptide with an 
irrelevant AFERQ motif (Supplemental Fig. 3A).
Deficiencies in CMA can frequently manifest as the intracellular accumulation of specific 
proteins which typically transit via this pathway into lysosomes for degradation. 
Immunoblotting analysis demonstrated increased cellular levels of two additional well-
established CMA substrates, phosphorylated IκBα (p-IκBα) and RNAse A (30, 31), in B 
cells with ectopic LAMP-2C expression pointing again to disruptions in CMA (Fig. 8B). 
Complexes of the chaperone HSC70 and CMA substrates can be detected in cells consistent 
with the formation of distinct transient complexes which promote substrate membrane 
translocation into lysosomes (12). The association of HSC70 with one of its substrates, 
cytoplasmic GAD, decreased suggesting that LAMP-2C likely perturbs the stability of these 
chaperone-substrate protein complexes required for CMA (Supplemental Fig. 3B). These 
findings suggest that increased expression of LAMP-2C in B cells obstructs chaperone 
association and the translocation of cytoplasmic peptides and proteins to selectively disrupt 
MHCII Ag presentation via CMA. Thus, LAMP-2C acts as a negative regulator of CMA in 
B lymphocytes.
Discussion
The current study examines the expression and a novel function of the conserved lysosomal 
membrane glycoprotein LAMP-2C in B lymphocytes MHCII Ag presentation. Like its 
homologous counterparts LAMP2A and LAMP2B, LAMP2C mRNA expression increased 
with B cell activation in response to TLR ligands or BCR crosslinking. Multiple gene 
products critical to Ag presentation are upregulated with B cell activation, and thus ectopic 
expression of LAMP-2C in B lymphoblasts was used to specifically explore the functions of 
this LAMP-2 isoform. Presentation of exogenous peptides and Ags was unaltered in B cells 
with increased LAMP-2C expression. Consistent with this finding, there was no change in 
MHCII surface expression or lysosomal protease activity in B lymphoblasts with increased 
LAMP-2C levels. T cell recognition of epitopes derived from membrane Ags or from an Ag 
that relies on MA was also unperturbed in B cells with enhanced LAMP-2C expression. By 
contrast, MHCII presentation of select cytoplasmic Ags via the CMA pathway was 
significantly diminished following LAMP-2C ectopic expression in B lymphoblasts. These 
results suggest LAMP-2C functions as a highly specific negative regulator of CMA in B 
lymphocytes.
Pérez et al. Page 10









LAMP-2A and -2B are constitutively expressed in most tissues and cells, but the 
mechanisms regulating each LAMP-2 isoform expression are not well understood. The 
global detection of these lysosomal proteins may be linked to the critical requirement for 
these isoforms in CMA and MA, processes important in tissue and cellular development, 
stress responses, and host immunity (9–11). LAMP-2A expression is essential for CMA and 
diminishes with aging and oxidative stress (14, 15, 25). LAMP-2B modulates lysosome 
maturation, with the absence of this protein slowing phagosome fusion and driving 
autophagosome accumulation (17). By contrast, LAMP-2C displays a unique profile of 
tissue-specific expression as shown here for humans and mice, as well as in published 
studies with rodent cells and organs (20). Quantitative analysis revealed human LAMP2A 
and LAMP2B mRNA levels were comparable in spleen and muscle, while LAMP2C 
message was significantly lower in spleen. By contrast, the expression of each isoform in 
murine tissues was reduced in the spleen compared with muscle or heart. Of note, cardiac 
and muscle defects are clinical hallmarks of Danon’s disease, a disorder linked to mutations 
in one or more of the human LAMP-2 isoforms (17). Low levels of LAMP2C mRNA were 
detected here in human B lymphocytes and by others in murine macrophage lines, 
suggesting a possible role in antigen recognition or clearance (20). The induction of 
LAMP2C with B cell activation in the current study also points to a potential role in 
immunity. B cell treatment with the TLR7 ligand R848 or TLR9 ligand CpG increased the 
mRNA expression of each LAMP2 isoform, although the fold increase was greatest for 
LAMP2C. BCR ligation also enhanced the expression of each LAMP2 isoform, with the 
greatest increase in LAMP2A and LAMP2B messages compared with LAMP2C. These 
results suggest specificity in the pathways leading to LAMP2C induction during B cell 
activation and potential roles for LAMP-2 isoforms in B cell engagement with Ags or 
pathogens.
B cell activation exerts multiple effects on Ag presentation pathways including increasing 
the expression of co-stimulatory and MHCII molecules, promoting the transit of HLA-DM 
to endosomal compartments, transporting the BCR to endosomes and autophagosomes, and 
promoting cytokine production which can impact T cell responses (26, 32, 33). Functional 
analyses of T cell recognition in the current study revealed LAMP-2C selectively impacts 
MHCII Ag presentation by blocking CMA and the acquisition of antigenic epitopes via this 
pathway. LAMP-2A functions as part of a translocator complex in CMA, moving proteins 
and peptides from the cytoplasm into lysosomes for processing. Increasing LAMP-2A 
expression in B cells enhanced MHCII presentation of several cytoplasmic autoantigens 
(19). This pathway for Ag presentation was also dependent on two important cytoplasmic 
chaperones, HSC70 and HSP90, which are required for CMA (19, 34). While LAMP-2A 
ectopic expression enhanced the translocation of cytoplasmic peptides into lysosomes for 
MHCII display (19), here LAMP-2C expression blocked cytoplasmic peptide translocation 
and MHCII presentation. LAMP-2C expression did not perturb MHCII presentation of 
exogenous and membrane Ags or Ag delivered by MA. Direct analysis of cellular levels of 
MA flux also indicated this process was not impaired with increased LAMP-2C expression. 
These results indicate LAMP-2C is not an inhibitor of LAMP-2B functions, as this latter 
isoform regulates lysosome fusion and maturation as well as the formation of 
autophagosomes (17). Thus, the induction of LAMP2C during B cell activation may alter the 
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profile of cytoplasmic but not extracellular antigenic epitopes displayed by MHCII through 
effects on CMA.
LAMP-2 isoforms differ predominantly in their C-terminal cytoplasmic tail domains with 
more conserved substitutions in their transmembrane and membrane proximal domains. The 
highly conserved glycosylated domain of each isoform extends into the lysosome lumen of 
most cells, and LAMP-2 is frequently used as a marker for lysosomes. However, upon T cell 
activation and in some tumors, LAMP-2 isoforms are delivered to the cell surface as 
secretory lysosomes fuse with the plasma membrane. By contrast, we have been unable to 
detect significant cell surface LAMP-2 expression in B cells (19). Each of the LAMP-2 
isoforms contains two cytoplasmic tail tyrosine motifs (YXXG and GYXX) important for 
membrane residence in lysosomes. LAMP-2 isoforms also contain two conserved glycine 
residues in their transmembrane domain, with studies of LAMP-2A indicating these are 
important in oligomerization required for CMA (35, 36). Whether mixed oligomers of 
LAMP-2 isoforms exist within lysosomes has not been determined, but could explain the 
ability of LAMP-2C to disrupt CMA and peptide translocation. In contrast with LAMP-2A, 
a peptide from the tail of LAMP-2C does not bind the CMA chaperone HSC70 (20). 
However, studies here revealed impaired association of HSC70 with the CMA substrate 
GAD in cells with increased LAMP-2C expression. These results suggest mechanistically 
LAMP-2C may alter chaperone capture of substrates for CMA translocation. Repeated 
attempts to detect the association of LAMP-2C with other LAMP-2 isoforms have not been 
successful in human B cells, although transient complex formation cannot be ruled out. 
Recently, LAMP-2C has been implicated in transporting DNA and RNA from the cytoplasm 
into lysosomes of cells (20, 21). This finding was based upon the ability of the cytoplasmic 
tail of LAMP-2C to bind nucleic acids and analysis of HeLa cells expressing LAMP-2C (20, 
21). Positively charged residues in the tail of LAMP-2C were implicated in nucleic acid 
binding, but a very similar motif of four positively charged residues is found in LAMP-2B 
which does not promote lysosomal nucleic acid transport. Additional studies are needed to 
define at a molecular level precisely how LAMP-2C disrupts CMA and whether nucleic 
acids play a role in this process.
Disruption of LAMP-2A and CMA in T cells revealed that this pathway regulates cellular 
levels of Itch, an ubiquitin ligase, and the calcineurin inhibitor RCAN1 likely by blocking 
their degradation (18). In B cells with increased LAMP-2C expression, the levels of two 
proteins which are targeted for degradation by CMA, RNAse A and p-IκBα were 
significantly increased, again consistent with a block in this autophagy pathway. No 
difference in the proliferation or survival of B cells was detected with LAMP-2C expression. 
These latter results suggest a novel role for LAMP-2C in regulating CMA, and together with 
the work in T cells, the importance of this selective autophagy pathway in lymphocyte 
functions.
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Refer to Web version on PubMed Central for supplementary material.
Pérez et al. Page 12










Supported by the National Institutes of Health grants R01AI1079065, T32AI060519, and T32HL007910, and IU 
Health Strategic Research Initiative in Oncology.
We thank Dr. Matthew Tector for providing human spleen and Dr. B. Paul Herring (IUSM) for providing muscle 
tissue.
Abbreviations used in this article
LAMP-2 lysosome-associated membrane protein-2
CMA chaperone-mediated autophagy
MA macroautophagy
MHCII MHC class II
References
1. Cresswell P. Invariant chain structure and MHC class II function. Cell. 1996; 84:505–507. 
[PubMed: 8598037] 
2. Mari MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariant-chain 
processing. Proc Natl Acad Sci USA. 1994; 91:2171–2185. [PubMed: 8134367] 
3. Riese RJ, Wolf PR, Bromme D, Natkin LR, Villadangos JA, Ploegh HL, Chapman HA. Essential 
role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. 
Immunity. 1996; 4:357–366. [PubMed: 8612130] 
4. Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM. Mediation by HLA-
DM of dissociation of peptides from HLA-DR. Nature. 1995; 375:802–806. [PubMed: 7596415] 
5. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers 
and facilitates peptide loading. Cell. 1995; 82:155–165. [PubMed: 7606781] 
6. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex 
class II and CD1 molecules. Nat Immunol. 2004; 5:685–692. [PubMed: 15224094] 
7. Aichinger G, Karlsson L, Jackson MR, Vestberg M, Vaughan JH, Teyton L, Lechler RI, Peterson 
PA. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of 
endogenous proteins. J Biol Chem. 1997; 272:29127–29136. [PubMed: 9360989] 
8. Li P, Haque MA, Blum JS. Role of disulfide bonds in regulating antigen processing and epitope 
selection. J Immunol. 2002; 169:2444–2450. [PubMed: 12193713] 
9. Schmid D, Münz C. Innate and adaptive immunity through autophagy. Immunity. 2007; 27:11–21. 
[PubMed: 17663981] 
10. Deretic V. Autophagy: an emerging immunological paradigm. J Immunol. 2012; 189:15–20. 
[PubMed: 22723639] 
11. Miller BC, Zhao Z, Stephenson LM, Cadwell K, Pua HH, Lee HK, Mizushima N, Iwasaki A, He 
YW, Swat W, Virgin HW IV. The autophagy gene ATG5 plays an essential role in B lymphocyte 
development. Autophagy. 2008; 4:309–314. [PubMed: 18188005] 
12. Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM. The chaperone-mediated autophagy 
receptor organizes in dynamic protein complexes at the lysosomal membrane. Mol Cell Biol. 
2008; 28:5747–5763. [PubMed: 18644871] 
13. Cuervo AM, Knecht E, Terlecky SR, Dice JF. Activation of a selective pathway of lysosomal 
proteolysis in rat liver by prolonged starvation. Am J Physiol. 1995; 269:C1200–C1208. [PubMed: 
7491910] 
14. Kiffin R, Christian C, Knecht E, Cuervo AM. Activation of chaperone-mediated autophagy during 
oxidative stress. Mol Biol Cell. 2004; 15:4829–4840. [PubMed: 15331765] 
15. Cuervo AM, Dice JF. Age-related decline in chaperone-mediated autophagy. J Biol Chem. 2000; 
275:31505–31513. [PubMed: 10806201] 
Pérez et al. Page 13









16. Crotzer VL, Glosson N, Zhou D, Nishino I, Blum JS. LAMP-2-deficient human B cells exhibit 
altered MHC class II presentation of exogenous antigens. Immunology. 2010; 131:318–330. 
[PubMed: 20518820] 
17. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, Mora M, Riggs JE, Oh SJ, Koga Y, Sue 
CM, Yamamoto A, Murakami N, Shanske S, Byrne E, Bonilla E, Nonaka I, DiMauro S, Hirano 
M. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon 
disease). Nature. 2000; 406:906–910. [PubMed: 10972294] 
18. Valdor R, Mocholi E, Botbol Y, Guerrero-Ros I, Chandra D, Koga H, Gravekamp C, Cuervo AM, 
Macian F. Chaperone-mediated autophagy regulates T cell responses through targeted degradation 
of negative regulators of T cell activation. Nat Immunol. 2014; 15:1046–1054. [PubMed: 
25263126] 
19. Zhou D, Ping L, Lin Y, Lott JM, Hislop AD, Canaday DH, Brutkiewicz RR, Blum JS. Lamp-2a 
facilitates MHC class II presentation of cytoplasmic antigens. Immunity. 2005; 22:571–581. 
[PubMed: 15894275] 
20. Fujiwara Y, Furuta A, Kikuchi H, Aizawa S, Hatanaka Y, Konya C, Uchida K, Yoshimura A, 
Tamai Y, Wada K, Kabuta T. Discovery of a novel type of autophagy targeting RNA. Autophagy. 
2013; 9:403–409. [PubMed: 23291500] 
21. Fujiwara Y, Kikuchi H, Aizawa S, Furuta A, Hatanaka Y, Konya C, Uchida K, Wada K, Kabuta T. 
Direct uptake and degradation of DNA by lysosomes. Autophagy. 2013; 9:1167–1171. [PubMed: 
23839276] 
22. Schmid D, Pypaert M, Münz C. Antigen-loading compartments for major histocompatibility 
complex class II molecules continuously receive input from autophagosomes. Immunity. 2007; 
26:79–92. [PubMed: 17182262] 
23. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Münz C. Endogenous 
MHC class II processing of a viral nuclear antigen after autophagy. Science. 2005; 307:593–596. 
[PubMed: 15591165] 
24. Deffit SN, Blum JS. Macronutrient deprivation modulates antigen trafficking and immune 
recognition through HSC70 accessibility. J Immunol. 2015; 194:1446–1453. [PubMed: 25589076] 
25. Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. 
Science. 1996; 273:501–503. [PubMed: 8662539] 
26. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen presentation. Annu Rev Immunol. 2013; 
31:443–473. [PubMed: 23298205] 
27. Lennon-Duménil AM, Bakker AH, Wolf-Bryant P, Ploegh HL, Lagaudrière-Gesbert C. A closer 
look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol. 2002; 
14:15–21. [PubMed: 11790528] 
28. Hastings KT, Lackman RL, Cresswell P. Functional requirements for the lysosomal thiol reductase 
GILT in MHC class II-restricted antigen processing. J Immunol. 2006; 177:8569–8577. [PubMed: 
17142755] 
29. Lich JD, Elliott JF, Blum JS. Cytoplasmic processing is a prerequisite for presentation of an 
endogenous antigen by major histocompatibility complex class II proteins. J Exp Med. 2000; 
191:1513–1523. [PubMed: 10790426] 
30. Cuervo AM, Hu W, Lim B, Dice JF. IκB is a substrate for a selective pathway of lysosomal 
proteolysis. Mol Biol Cell. 1998; 9:1995–2010. [PubMed: 9693362] 
31. McElligott MA, Miao P, Dice JF. Lysosomal degradation of ribonuclease A and ribonuclease S-
protein microinjected into the cytosol of human fibroblasts. J Biol Chem. 1985; 260:11986–11993. 
[PubMed: 4044585] 
32. Clark MR, Massenburg D, Siemasko K, Hou1 P, Zhang M. B-cell antigen receptor signaling 
requirements for targeting antigen to the MHC class II presentation pathway. Curr Opin Immunol. 
2004; 16:382–387. [PubMed: 15134789] 
33. Chaturvedi A, Dorward D, Pierce SK. The B cell receptor governs the subcellular location of Toll-
like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity. 2008; 28:799–
809. [PubMed: 18513998] 
34. Houlihan JL, Metzler JJ, Blum JS. HSP90α and HSP90β isoforms selectively modulate MHC class 
II antigen presentation in B cells. J Immunol. 2009; 182:7451–7458. [PubMed: 19494268] 
Pérez et al. Page 14









35. Cuervo AM, Dice JF. Unique properties of lamp2a compared to other lamp2 isoforms. J Cell Sci. 
2000; 113:4441–4450. [PubMed: 11082038] 
36. Rout AK, Strub MP, Piszczek G, Tjandra N. Structure of transmembrane domain of lysosomal-
associated membrane protein type 2a (LAMP-2A) reveals key features for substrate specificity in 
chaperone-mediated autophagy. J Biol Chem. 2014; 289:35111–35123. [PubMed: 25342746] 
Pérez et al. Page 15









Figure 1. LAMP2 isoform expression and regulation during B cell activation
(A) Exon structure and alternative splicing of human LAMP2. The three isoforms have an 
identical luminal domain but distinct transmembrane and cytoplasmic domains. (B) RT-PCR 
analysis for LAMP2 isoforms in human tissues. LAMP2A and LAMP2B are ubiquitously 
expressed while LAMP2C is tissue specific. (C) Peripheral blood human B cells were treated 
for 24 h with R848, CpG, or left untreated (NS). Gene expression of LAMP2 isoforms and 
CD86 were analyzed by qPCR. (D) B cell TLR7 or TLR9 stimulation was detected via IL-6 
release. (E) Peripheral blood B cells were stimulated for 24 h to crosslink BCR or left 
untreated (NS). LAMP2 isoforms and CD86 mRNA were detected as in (C). Data were 
analyzed by two-way ANOVA (C and E) or by one-way ANOVA (D). *p < 0.05, ***p < 
0.001, and ****p < 0.0001 (mean ± SD, n = 3).
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Figure 2. Inhibition of MHCII cytoplasmic Ag presentation in B cells ectopically expressing 
LAMP-2C
(A) PG zeo and PG 2c B cells with ectopic LAMP-2C were incubated with GAD-specific T 
cells to analyze T cell activation. (B) As a control, PG zeo and PG 2c B cells were incubated 
with 10 μM of GAD273-285 peptide for 4 h and cultured with GAD-specific T cells at APC:T 
cell ratio of 0.05:1 to monitor MHCII presentation. (C) FS pCMV and FS 2c B cells were 
incubated with κ-specific T cells at APC:T cell ratio of 1:1 to detect T cell activation. (D) 
FS pCMV and FS 2c B cells were incubated overnight with 10 μM of κ188-203 peptide and 
cultured with κ-specific T cells at APC:T cell ratio of 1:1 to measure T cell activation. Data 
were analyzed by two-way ANOVA (A) or by two-tailed, unpaired Student t test (C). **p < 
0.01 and ***p < 0.001 (mean ± SD, representative of n 3).
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Figure 3. LAMP-2C expression did not alter the MHCII presentation of exogenous Ags
(A) B cells +/− ectopic LAMP-2C expression were incubated overnight with 20 μM of HSA 
Ag or 4 h with 10 μM HSA64-76 peptide and then cultured with HSA-specific T cells to 
measure T cell activation. (B) PG zeo and PG 2c B cells were incubated overnight with 0.1 
μM of TT Ag or for 4 h with 0.2 μM of TT peptides. APCs were cultured with TT-specific T 
cells to analyze T cell activation. (mean ± SD, representative of n 3).
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Figure 4. MHCII presentation of self or viral membrane proteins was not affected by LAMP-2C 
overexpression
(A and B) PG zeo and PG 2c B cells were cultured with κI- or κII-specific T cells. T cell 
activation was monitored to analyze MHCII presentation of membrane Ag, Ig κ. (C) PG zeo 
and PG 2c B cells were infected overnight with influenza A X-31, A/Aichi/68 (H3N2) or 
incubated with HA307-319 peptide for 4 h and then cultured with HA-specific T cells to 
measure T cell activation. (mean ± SD, representative of n 3).
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Figure 5. Macroautophagy was not altered with B cell ectopic LAMP-2C expression
(A) PG zeo and PG 2c B cells were transduced to express the chimeric Ag MP1-LC3. MP1-
LC3 is targeted to autophagosomes by the LC3 domain. APCs were cultured with MP1-
specific T cells to monitor T cell activation. (B) PG zeo and PG 2c B cells were incubated 
overnight +/− 20 μM CQ, an inhibitor of lysosome acidification, to monitor autophagosome 
formation and turnover. MA flux was evaluated by immunoblotting to detect changes in 
cellular LC3II levels +/− CQ. (mean ± SD, representative of n = 2–3).
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Figure 6. Changes in cytoplasmic MHCII-restricted presentation were not due to differential 
expression of proteins required for Ag presentation or CMA
(A and B) Lysates from PG zeo and PG 2c B cells were resolved by SDS-PAGE and 
immunoblotted to detect LAMP-2, GAD, HSC70, HSP90, LAMP-1, HLA-DR dimer, HLA-
DR α chain, Ii, actin, and GAPDH. (C) PG zeo and PG 2c B cells were incubated with Abs 
to detect cell surface expression of HLA-DR, HLA-DQ, HLA-DP, or CLIP and total cellular 
levels of HLA-DO. (mean ± SD, representative of n 4).
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Figure 7. Cellular lysosomal enzyme levels and proteolytic processing by cathepsins and the 
proteasome were unaffected by ectopic expression of LAMP-2C in B cells
(A) Comparable maturation of CatD and GILT in B cells expressing LAMP-2C. Lysates 
from PG zeo and PG 2c B cells were resolved by SDS-PAGE and immunoblotted to detect 
the precursor (p), intermediate (i) or mature (m) form of CatD or GILT. (B) To analyze CatL 
or CatB activities, PG zeo and PG 2c B cells were incubated for 30 min at 37°C with 
membrane permeable fluorogenic substrates specific for CatL or CatB. Enzyme activity was 
detected by flow cytometry. (C) Proteasome activity was determined by incubating PG zeo 
and PG 2c B cells with a luminogenic chymotrypsin-like substrate. (mean ± SD, 
representative of n = 2–4).
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Figure 8. Decreased peptide translocation from the cytoplasm to endosomal MHCII molecules 
and reduced processing of CMA substrates
(A) PG zeo and PG 2c B cells were incubated with 2 mM GAD273-285-biotin and 
electroporated to deliver this peptide to the cytoplasm. Control cells were not subjected to 
electroporation. Cells were acid- stripped, cultured 16 h, and lysates resolved by SDS-
PAGE. Streptavidin-HRP was used to detect biotin-peptide complexed with MHCII 
molecules. Immunoblotting of actin was used as a loading control. (B) Basal levels of CMA 
substrates p-IκBα and RNAse A were evaluated by immunoblotting. Data were analyzed by 
two-way ANOVA. ***p < 0.001 (mean ± SD, n = 3–4).
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